Exam 11: Pharmaceuticals
Exam 1: Choices: Money, Medicine, and Health30 Questions
Exam 2: Demand and Supply30 Questions
Exam 3: Cost-Benefit and Cost-Effectiveness Analysis30 Questions
Exam 4: Health Insurance: Financing Medical Care30 Questions
Exam 5: Insurance Contracts and Managed Care29 Questions
Exam 6: Physicians30 Questions
Exam 7: Medical Education, Organization, and Business Practices30 Questions
Exam 8: Hospitals30 Questions
Exam 9: Management and Regulations of Hospital Costs29 Questions
Exam 10: Long-Term Care30 Questions
Exam 11: Pharmaceuticals30 Questions
Exam 12: Financing and Ownership of Health Care Providers29 Questions
Exam 13: Macroeconomics and Medical Care30 Questions
Exam 14: The Role of Government and Public Goods30 Questions
Exam 15: History, Demography, and the Growth of Modern Medicine30 Questions
Exam 16: International Comparisons of Health and Health Expenditures31 Questions
Exam 17: Economic Evaluation of Health Policy: The Patient Protection and Affordable Care Act of 201030 Questions
Exam 18: Value for Money in the Future of Health Care30 Questions
Select questions type
What is the average time period for the introduction of a new drug into market?
(Multiple Choice)
4.8/5
(85)
One of the common tasks for pharmacoeconomists employed by large pharmaceutical companies is performing a cost effectiveness study of a new drug.
(True/False)
4.8/5
(82)
Costs structure in the pharmaceutical industry is largely characterized by fixed expenses which are proportional to output levels.
(True/False)
4.8/5
(87)
Explain why R&D by surgeons in hospitals can be expected to lead to more process innovations than product innovations. Compare the regulation of surgeons' use of new surgical skills with the regulation of new drugs.
(Essay)
5.0/5
(88)
Phase I of FDA testing involves human testing for efficacy of an Investigational New Drug (IND).
(True/False)
5.0/5
(75)
On average, government-funded expenditures on prescription drugs are about $200 per person per year.
(True/False)
4.9/5
(74)
What does the term "detailing" mean in the pharmaceutical industry?
(Multiple Choice)
4.7/5
(72)
Economies of scale are a common feature of R&D in the pharmaceutical industry.
(True/False)
4.8/5
(82)
Many mail-order pharmacies these days are owned by PBMs. Addressing the concerns that such ownership might lead to a conflict of interest, the Federal Trade Commission (FTC) launched an investigation into this practice and published its report "Pharmacy Benefits Managers: Ownership of Mail-Order Pharmacies" in 2005. The report found, however, that there were no significant differences between the practices of the two types of mail-order pharmacies, including no significant differences in the use of generics between PBM-owned (35% of all dispensed drugs) vs. non-PBM owned (36% of all dispensed drugs) mail-order pharmacies. Discuss what could be a valid explanation behind this finding.
(Essay)
4.8/5
(81)
The proportion of expenditures paid out of pocket for pharmaceuticals today is greater than the fraction of expenditures paid out of pocket for physician or hospital services.
(True/False)
4.9/5
(75)
Showing 21 - 30 of 30
Filters
- Essay(0)
- Multiple Choice(0)
- Short Answer(0)
- True False(0)
- Matching(0)